Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia®
Retrospective Study of Nearly 375,000 Type 2 Diabetes Patients Presented at American Heart Association 2010 Scientific Sessions
http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=531328
A retrospective study of nearly 375,000 type 2 patients evaluating the incidence of events related to cardiovascular disease (CVD) and all-cause hospitalizations among initiators of BYETTA® (exenatide) injection compared to initiators of other commonly used diabetes medications. BYETTA was associated with a lower incidence of CVD-related events than insulin, thiazolidinediones (TZDs) and sulfonylureas and a comparable incidence versus metformin and Januvia® (sitagliptin).
Retrospective Study of Nearly 375,000 Type 2 Diabetes Patients Presented at American Heart Association 2010 Scientific Sessions
http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=531328
A retrospective study of nearly 375,000 type 2 patients evaluating the incidence of events related to cardiovascular disease (CVD) and all-cause hospitalizations among initiators of BYETTA® (exenatide) injection compared to initiators of other commonly used diabetes medications. BYETTA was associated with a lower incidence of CVD-related events than insulin, thiazolidinediones (TZDs) and sulfonylureas and a comparable incidence versus metformin and Januvia® (sitagliptin).
